SCYNEXIS, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
SCYNEXIS, Inc. (SCYX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-29.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2021-03-29
- SCYNEXIS, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $0.00.
- SCYNEXIS, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-09-30 was $0.00.
- SCYNEXIS, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-06-30 was $0.00.
- SCYNEXIS, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- SCYNEXIS, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $3.37M.
- SCYNEXIS, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2018 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $0.00 derived: sum of 2 quarters · filed 2021-03-29 | $0.00 derived: sum of 3 quarters · filed 2021-03-29 | $0.00 10-K · filed 2021-03-29 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | $0.00 derived: sum of 4 quarters · filed 2021-03-29 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | $0.00 derived: sum of 3 quarters · filed 2021-03-29 | $0.00 derived: sum of 4 quarters · filed 2021-03-29 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-03-29 | $0.00 derived: sum of 3 quarters · filed 2021-03-29 | $0.00 derived: sum of 4 quarters · filed 2021-03-29 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $0.00 derived: sum of 2 quarters · filed 2021-03-29 | $0.00 derived: sum of 3 quarters · filed 2021-03-29 | $3.37M 10-K · filed 2021-03-29 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $3.37M 10-Q · filed 2020-11-06 | $3.37M derived: sum of 4 quarters · filed 2020-11-06 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $3.37M 10-Q · filed 2020-08-10 | $3.37M derived: sum of 3 quarters · filed 2020-08-10 | $3.37M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $3.37M 10-Q · filed 2020-05-11 | $3.37M derived: sum of 2 quarters · filed 2020-05-11 | $3.37M derived: sum of 3 quarters · filed 2020-05-11 | $3.37M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $0.00 derived: sum of 2 quarters · filed 2020-03-11 | $0.00 derived: sum of 3 quarters · filed 2020-03-11 | $0.00 10-K · filed 2020-03-11 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $0.00 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $0.00 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |